Int. J. Mol. Sci. 2018, 19(3), 673 Abstract Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as [...]
TASECTAN® launched in Croatia by JGL. Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and [...]
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée. XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the [...]
Aloi M, Mennini M. J Comp Eff Res. 2018 Nov 22. Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis. AIM: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis. METHODS: A comprehensive literature search [...]
Allergy, Asthma & Clinical Immunology2018 Abstract: Background To assess the effects of Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary function (in MucilAir™Nasal cells). Methods MucilAir™Nasal, a three-dimensional organotypic airway tissue model (with different cell types), was treated with Rhinosectan® (30 µl) or with a control (saline solution). The effects of [...]
De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37 Allergy Asthma Clin Immunol. 2017 Aug 10;13:37 Full text free!! Abstract: Background: To evaluate barrier protective properties [...]
Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI – European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce [...]
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them [...]
M. Lanza1, I. Paterniti1, M. Campolo1 ,G. Casili1 , A. Filippone1,A. Peritore1, S. Cuzzocrea1,2 ,E. Esposito1 1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina- Messina, Italy 2Department of Pharmacological and Physiological Science, Saint Louis University, South Grand Blvd St. Louis, Missouri, USA Beneficial effect of the combination [...]
For the third consecutive year, Noventure has participated in the annual congress of the EAU – European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world. During the Congress 273 scientific sessions included 2,656 presentations [...]